Kidney medicine · 2025
Development and Evaluation of a Culturally Targeted Apolipoprotein L1 Counseling Training Program for Transplant Clinicians: A Pilot Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gordon Elisa J, Gacki-Smith Jessica, Manning Dahlya, Wicklund Catherine, Duquette Debra, Yancy Clyde W, Muhammad Lutfiyya N, Dong Siyuan, Friedewald John, Gilbert Alexander, Cooper Matthew, Smith Justin D, Shetty Aneesha, Agrawal Akansha
Аннотация
RATIONALE & OBJECTIVE: Apolipoprotein L1 (APOL1) genetic testing is increasingly used to evaluate potential living kidney donors (pLDs) of African ancestry. Transplant clinicians may benefit from improving knowledge and skills in delivering APOL1 counseling. This multisite study developed and evaluated the effectiveness of a culturally targeted Counseling Training Program on APOL1 and Living Donation ("Training Program") to train transplant clinicians on APOL1 biology, genetics, and genetic counseling.
STUDY DESIGN: A prospective, nonrandomized pretest/posttest clinical trial.
SETTING & PARTICIPANTS: Transplant nephrologists, surgeons, nurses, advanced practice providers, and general nephrologists at 6 kidney transplant centers.
INTERVENTION: The training program included 8 prerecorded videos about APOL1 and living kidney donation, counseling skills, cultural sensitivity, and shared decision making.
OUTCOMES: Knowledge and self-efficacy in genetic counseling, knowledge of genetic variation, use of race in clinical decision making, and beliefs about the relationship between genetics and race, as assessed via validated surveys.
ANALYTIC APPROACH: Paired tests of pre-post scores from validated surveys.
RESULTS: In total, 35 clinicians participated; 21 were female, and 34 had no formal genetics training. Training program exposure was significantly associated with an increase in knowledge of genetic variation: pre, 3.31 (1.41); post, 3.91 (1.27), P = 0.04. Participants reported increased confidence post-training in their ability to know when the APOL1 genetic test is indicated (P = 0.001), interpret APOL1 test results (P < 0.001), and communicate about APOL1 in a culturally sensitive manner (P < 0.001). There was a nonsignificant decrease in beliefs about relationships between genetics and race from pretest to posttest (biologic domain: pre, 9.63 (3.06); post, 9.06 (2.76), P = 0.32; clinical domain, pre, 11.03 (2.22); post, 10.57 (2.63), P = 0.36).
LIMITATIONS: Small sample size and nonrandomized design.
CONCLUSIONS: Our findings suggest the training program can increase transplant clinicians' competence in counseling pLDs about APOL1 genetic testing. Training program dissemination may facilitate integration of APOL1 testing and counseling into pLD evaluation nationally.
STUDY DESIGN: A prospective, nonrandomized pretest/posttest clinical trial.
SETTING & PARTICIPANTS: Transplant nephrologists, surgeons, nurses, advanced practice providers, and general nephrologists at 6 kidney transplant centers.
INTERVENTION: The training program included 8 prerecorded videos about APOL1 and living kidney donation, counseling skills, cultural sensitivity, and shared decision making.
OUTCOMES: Knowledge and self-efficacy in genetic counseling, knowledge of genetic variation, use of race in clinical decision making, and beliefs about the relationship between genetics and race, as assessed via validated surveys.
ANALYTIC APPROACH: Paired tests of pre-post scores from validated surveys.
RESULTS: In total, 35 clinicians participated; 21 were female, and 34 had no formal genetics training. Training program exposure was significantly associated with an increase in knowledge of genetic variation: pre, 3.31 (1.41); post, 3.91 (1.27), P = 0.04. Participants reported increased confidence post-training in their ability to know when the APOL1 genetic test is indicated (P = 0.001), interpret APOL1 test results (P < 0.001), and communicate about APOL1 in a culturally sensitive manner (P < 0.001). There was a nonsignificant decrease in beliefs about relationships between genetics and race from pretest to posttest (biologic domain: pre, 9.63 (3.06); post, 9.06 (2.76), P = 0.32; clinical domain, pre, 11.03 (2.22); post, 10.57 (2.63), P = 0.36).
LIMITATIONS: Small sample size and nonrandomized design.
CONCLUSIONS: Our findings suggest the training program can increase transplant clinicians' competence in counseling pLDs about APOL1 genetic testing. Training program dissemination may facilitate integration of APOL1 testing and counseling into pLD evaluation nationally.